Patient groups fail to declare financial interests during NICE assessments

16 January 2019 - Patients’ groups involved in assessing treatments for the NHS often fail to disclose their financial interests, ...

Read more →

Challenges and methodologies in using progression free survival as a surrogate for overall survival in oncology

11 July 2018 - A primary outcome in oncology trials is overall survival. However, to estimate overall survival accurately requires ...

Read more →

Effect of cross-over in oncology clinical trials on evidence levels in early benefit assessment in Germany

13 June 2018 - In oncology clinical trials, cross-over is used frequently but may lead to uncertainties regarding treatment effects. ...

Read more →

Metastatic breast cancer: highly selective post-hoc analysis rather than complete publication of quality of life data

13 June 2018 - IQWiG employees criticise the publication practice of PALOMA-2 study authors. ...

Read more →

Canada's regulator of patented drug prices is rigging data, and risking our health

5 December 2017 - The patent medicine pricing board is making a blatant attempt to bias the data. ...

Read more →

Drugs watchdog NICE attacks pharmaceutical industry in pricing dispute

25 September 2017 - Industry expert’s evidence is not independent, NICE argues. ...

Read more →

Managing conflicts of interest – making good decisions

24 July 2017 - NICE is seeking views on a new conflicts of interest policy to ensure its committees’ decisions ...

Read more →

Tackling submission and publication bias

17 July 2017 - Evoniuk and colleagues analysed whether submission and publication bias are based on study outcome. ...

Read more →

Addressing bias and conflict of interest among biomedical researchers

2 May 2017 - Bias in research is ubiquitous and the goal of every researcher should be to reduce bias and ...

Read more →

Big pharma funding biases drug trials in favour of a sponsor's product: review

21 February 2017 - Drug and device trial studies that are sponsored by the pharmaceutical industry are more likely to ...

Read more →

Confounding by indication in clinical research

1 November 2016 - In the assessment of the effect of a treatment or potential risk factor—termed an exposure—on a patient ...

Read more →